376 completed, 101 unknown, 77 terminated, 45 recruiting. 661 Phase 3, 151 Phase 2.
Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria | Phase 3 | Not yet recruiting | Indiana University | 1500 | 2028-01-01 | 2026-09-01 |
| To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS). Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC., Controls will receive two infusions of vehicle solution. - Acute Respiratory Distress Syndrome | Phase 3 | Not yet recruiting | Breathe Biologics, Inc. | 128 | 2027-03-01 | 2026-10-01 |
| Prediction and Prevention of Bloodstream Infections After Kidney Transplantation Pivmecillinam, Placebo - Kidney Transplant Infection, Bloodstream Infection | Phase 3 | Not yet recruiting | Susanne Dam Nielsen, MD, DMSc | 180 | 2027-01-01 | 2026-10-16 |
| Naproxen Versus Placebo as Adjunct Treatment of Cellulitis enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious | Phase 3 | Not yet recruiting | Ottawa Hospital Research Institute | 884 | 2026-11-01 | 2026-10-20 |
| A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response Fludrocortisone 50 mcg daily, Fludrocortisone 100 mcg daily, Placebo - Septic Shock | Phase 3 | Recruiting | The George Institute | 2200 | 2026-10-16 | 2026-10-27 |
| Effect of Adjunctive Ursodeoxycholic Acid on Oxidative Stress, Inflammation, and Organ Dysfunction in Adults With Sepsis Standard medical treatment, Ursodeoxycholic Acid - Sepsis | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 80 | 2026-10-01 | 2026-10-07 |
| STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis Hydrocortisone administration, Expanded antimicrobial therapy - Sepsis, Tuberculosis | Phase 3 | Not yet recruiting | University of Virginia | 344 | 2026-10-01 | 2026-06-01 |
| THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT: THE PROMISE DOUBLE BLIND, PHASE III, RANDOMIZED CONTROLLED CLINICAL TRIAL Meropenem Infusion, Sodium Chloride (NaCl) 0.9 % - Sepsis | Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 398 | 2026-10-01 | 2026-10-26 |
| The Effect of Nicorandil on Rheumatoid Arthritis Patients Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 70 | 2026-09-06 | 2026-09-16 |
| Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock Dexmedetomidine 100 µg/mL, intravenous solution, Stardard care - Septic Shock, Vasopressor Resistance | Phase 3 | Not yet recruiting | Hospices Civils de Lyon | 360 | 2026-09-01 | 2026-05-06 |
| CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL Placebo, clarithromycin - Sepsis | Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 252 | 2026-09-01 | 2026-10-28 |
| Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled Trial Dexamethasone, Placebo - Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Recruiting | Southeast University, China | 1704 | 2026-08-27 | 2026-09-02 |
| Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis alpha lipoic acid 600 mg twice daily, Placebo Tablet - Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 50 | 2026-07-27 | 2026-07-30 |
| Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients Melatonin - Therapy, Treatment | Phase 2 / Phase 3 | Not yet recruiting | Ain Shams University | 64 | 2026-07-21 | 2026-07-23 |
| Colchicine for the Prevention of Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Single-Center, Strategy-Stratified, Randomized, Double-Blind, Placebo-Controlled Trial Colchicine 0.5 MG oral tablet twice daily, Placebo Oral Tablet - Post-Operative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG) | Phase 2 / Phase 3 | Enrolling by invitation | National Taiwan University Hospital | 400 | 2026-07-06 | 2026-07-10 |
| Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction Dapaglifozin, Placebo - Septic Shock | Phase 3 | Not yet recruiting | University Hospital, Strasbourg, France | 568 | 2026-07-01 | 2026-03-27 |
| Colchicine for Autoimmune and Subacute Thyroiditis colchicine, Prednisolone, NSAID - Hashimoto Thyroiditis, Subacute Thyroiditis | Phase 2 / Phase 3 | Recruiting | Mansoura University | 300 | 2026-06-15 | 2026-07-29 |
| Design and Rationale of the COLT Study Colchicine 0.5 MG Oral Tablet, Placebo - Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome | Phase 3 | Not yet recruiting | Azienda Sanitaria Locale ASL 6, Livorno | 940 | 2026-06-01 | 2026-02-25 |
| Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation Ketofol, propofol (drug) - The Critically Ill Patient is Requiring Intubation, Septic Shock | Phase 3 | Active not recruiting | Helwan University | 70 | 2026-05-13 | 2026-10-15 |
| Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT Phosphate-containing Replacement Fluid, Standard Phosphate-free Replacement Fluid - Acute Kidney Injury, Sepsis | Phase 3 | Not yet recruiting | Sun Yat-sen University | 220 | 2026-05-01 | 2026-04-24 |
Showing 20 of 661. Sign in to see all of them.
Sepsis (209) · Shock, Septic (132) · Cellulitis (37) · COVID-19 (32) · Bacteremia (27) · Infections (27) · Cytokine Release Syndrome (24) · Neonatal Sepsis (24) · Pain (22) · Pneumonia (22) · Abscess (20) · Candidemia (20) · Cataract (17) · Shock (15)
Pathological Conditions, Signs and Symptoms (661) · Pathologic Processes (655) · Infections (418) · Systemic Inflammatory Response Syndrome (351) · Shock (159) · Sepsis (125) · Respiratory Tract Diseases (105) · Lung Diseases (83) · Bacterial Infections and Mycoses (82) · Respiratory Tract Infections (70) · Cardiovascular Diseases (66) · Signs and Symptoms (64) · Skin and Connective Tissue Diseases (62) · Suppuration (54)
Saline Solution (28) · Sodium Chloride (24) · Vancomycin (20) · Hydrocortisone (16) · Ascorbic Acid (15) · Colchicine (13) · Meropenem (13) · Norepinephrine (13) · Standard of Care (12) · Fluconazole (10) · Linezolid (10) · Trimethoprim, Sulfamethoxazole Drug Combination (10) · Daptomycin (9) · Cholecalciferol (8) · Methylene Blue (8)
Assistance Publique - Hôpitaux de Paris (16) · Pfizer (12) · Bausch & Lomb Incorporated (11) · Ain Shams University (10) · Hellenic Institute for the Study of Sepsis (8) · Radboud University Medical Center (8) · Cairo University (6) · Emory University (6) · University of Versailles (6) · Amgen (5) · Astellas Pharma Inc (5) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (5) · McMaster University (5) · Sirion Therapeutics, Inc. (5) · University of Virginia (5)
United States (197) · France (88) · Canada (75) · Italy (61) · Spain (60) · Brazil (58) · Germany (57) · United Kingdom (43) · Netherlands (42) · Belgium (37) · China (31) · Israel (31) · Russia (31) · Egypt (30) · Greece (26)
Roger Vogel, MD (4) · Ahmed Mukhtar, Professor (3) · Allison B. Goldfine, MD (3) · Djillali Annane, MD, PhD (3) · Jon E. Tyson, MD MPH (3) · Konrad Reinhart, MD (3) · Abbot R. Laptook, MD (2) · Anders Perner, MD, PhD (2) · Andrea Morelli, MD (2) · Andrew Schwartz, MD (2)
PMID 28459966, PMID 28597967, PMID 33891293, PMID 37316690, PMID 30018799, PMID 30597021, PMID 30716446, PMID 31077258, PMID 31280481, PMID 31909868, PMID 34536218, PMID 34741280, PMID 34905144, PMID 34922058, PMID 37916745, PMID 12424394, PMID 14977340, PMID 19101421, PMID 20695801, PMID 21115456, PMID 21147825, PMID 21615299, PMID 23525934, PMID 23984731, PMID 24136301, PMID 24635772, PMID 24897082, PMID 24935281, PMID 27370913, PMID 27585969, PMID 27695824, PMID 27810317, PMID 28670710, PMID 29358292, PMID 32965495, PMID 33006765, PMID 33438477, PMID 33599960, PMID 34976290, PMID 36915146, PMID 42192627, PMID 10371570, PMID 10722036, PMID 10933646, PMID 1138591, PMID 11502226, PMID 11588440, PMID 12145720, PMID 12454520, PMID 12500513
2025 (6), 2018 (5), 2005 (4), 2009 (4), 2017 (4), 2023 (4), 2014 (3), U10HD021373 (3), U10HD021385 (3), U10HD021397 (3), 2015 (2), M01RR000070 (2), M01RR000750 (2), M01RR006022 (2), M01RR008084 (2)